晚期慢性肝病患者丙型肝炎病毒清除后的无创风险分层
本研究纳入276例治疗前存在晚期慢性肝病且获得HCV治愈的患者,评估治疗后肝硬度(FU-LSM)和血管性血友病因子/血小板比值(FU-VITRO)对肝功能失代偿和肝细胞癌的预测价值。结果显示两者对肝功能失代偿预测性能优异(AUROC分别为0.875和0.925),联合算法可区分低危、高危和灰区患者,3年肝功能失代偿风险分别为0%、17.4%和2.6%。
要点
- FU-LSM和FU-VITRO对HCV治愈后肝功能失代偿具有强且独立的预测价值。
- 联合算法将57.3%患者归为低危组,该组无肝功能失代偿发生。
- 高危组(25.0%)3年肝功能失代偿风险为17.4%,灰区组(17.8%)为2.6%。
核心结论
- FU-LSM/FU-VITRO对HCV诱导的晚期慢性肝病患者治疗后肝功能失代偿具有强且独立的预测作用。
- 联合这些无创标志物的算法不仅能排除或确认FU-CSPH,还能识别肝功能失代偿风险极低与高危的人群。
- FU-LSM/FU-VITRO易于获取,可在持续病毒学应答后实现风险分层,从而促进个体化管理。
研究设计与样本
- 研究纳入276例治疗前存在晚期慢性肝病且获得HCV治愈的患者,均有治疗前及治疗后随访的LSM和FU-VITRO信息。
- 患者在接受无干扰素治疗后中位随访36.6个月。
- 研究在内部验证队列(n=86)和外部验证队列(n=162)中验证了算法的预后价值。
主要发现
- FU-LSM对肝功能失代偿的AUROC为0.875(95%CI:0.796-0.954)。
- FU-VITRO对肝功能失代偿的AUROC为0.925(95%CI:0.874-0.977)。
- FU-LSM和FU-VITRO均提供增量信息,在校正模型中与肝功能失代偿显著相关。
- 联合算法将57.3%的患者归为低危组(FU-LSM<12.4 kPa和/或FU-VITRO<0.95),该组无患者发生肝功能失代偿。
- 高危组(FU-LSM>25.3 kPa和/或FU-VITRO>3.3,占25.0%)治疗后3年肝功能失代偿风险为17.4%;灰区组(17.8%)随访期间肝功能失代偿风险为2.6%。
关键数值与推荐
- 排除FU-CSPH的标准:FU-LSM<12.4 kPa和/或FU-VITRO<0.95。
- 确认FU-CSPH的标准:FU-LSM>25.3 kPa和/或FU-VITRO>3.3。
- FU-CSPH诊断灰区:未满足上述排除或确认标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Risk stratification after cure from hepatitis C virus (HCV) infection remains a clinical challenge. We investigated the predictive value of noninvasive surrogates of portal hypertension (liver stiffness measurement [LSM] by vibration-controlled transient elastography and von Willebrand factor/platelet count ratio [VITRO]) for development of hepatic decompensation and hepatocellular carcinoma in patients with pretreatment advanced chronic liver disease (ACLD) who achieved HCV cure. APPROACH AND RESULTS: A total of 276 patients with pretreatment ACLD and information on pretreatment and posttreatment follow-up (FU)-LSM and FU-VITRO were followed for a median of 36.6 months after the end of interferon-free therapy. FU-LSM (area under the receiver operating characteristic curve [AUROC]: 0.875 [95% confidence interval [CI]: 0.796-0.954]) and FU-VITRO (AUROC: 0.925 [95% CI: 0.874-0.977]) showed an excellent predictive performance for hepatic decompensation. Both parameters provided incremental information and were significantly associated with hepatic decompensation in adjusted models. A previously proposed combined approach (FU-LSM < 12.4 kPa and/or FU-VITRO < 0.95) to rule out clinically significant portal hypertension (CSPH, hepatic venous pressure gradient ≥10 mm Hg) at FU assigned most (57.3%) of the patients to the low-risk group; none of these patients developed hepatic decompensation. In contrast, in patients in whom FU-CSPH was ruled in (FU-LSM > 25.3 kPa and/or FU-VITRO > 3.3; 25.0% of patients), the risk of hepatic decompensation at 3 years following treatment was high (17.4%). Patients within the diagnostic gray-zone for FU-CSPH (17.8% of patients) had a very low risk of hepatic decompensation during FU (2.6%). The prognostic value of this algorithm was validated in an internal (n = 86) and external (n = 162) cohort. CONCLUSION: FU-LSM/FU-VITRO are strongly and independently predictive of posttreatment hepatic decompensation in HCV-induced ACLD. An algorithm combining these noninvasive markers not only rules in or rules out FU-CSPH, but also identifies populations at negligible versus high risk for hepatic decompensation. FU-LSM/FU-VITRO are readily accessible and enable risk stratification after sustained virological response, and thus facilitate personalized management.
引用
- Semmler G, Binter T, Kozbial K, et al. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology. 2021. PMID: 32659847. doi:10.1002/hep.31462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。